This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro, Rachel Abrams and Natalie Kitroeff. Twenty minutes a day, five days a week, ready by 6 a.m. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York ...
…
continue reading
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
S6 Ep28: Biosimilars Dermatology Roundup for March 2024—Podcast Edition
MP3•Episode home
Manage episode 409826161 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Show notes
- AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
- Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics
- Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
- Adalimumab Expenditures in Countries With and Without Available Biosimilars
- Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
- Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
- Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
157 episodes
MP3•Episode home
Manage episode 409826161 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Show notes
- AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
- Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics
- Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
- Adalimumab Expenditures in Countries With and Without Available Biosimilars
- Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
- Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
- Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
157 episodes
Wszystkie odcinki
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.